EUROASPIRE V and uncontrolled risk factors in primary prevention: Atherosclerotic cardiovascular disease in the making

EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569–1582.

Group EIS. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.

Kotseva K Wood D De Backer G , et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121–137.

Kotseva K Wood D De Bacquer D , et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636–648.

Kotseva K De Backer G De Bacquer D , et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol 2019; 26: 824–835.

Santos RD. Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself. Eur J Prev Cardiol 2019; 26: 820–823.

Blom DJ Santos RD Daclin V , et al. The challenge of multiple cardiovascular risk factor control outside Western Europe: findings from the International ChoLesterol management Practice Study. Eur J Prev Cardiol, Epub ahead of print 19 September 2019. DOI: 10.1177/2047487319871735.

Grundy SM Stone NJ Bailey AL , et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 2019; 73: e285–e350.

Mach F Baigent C Catapano AL , et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–188.

Fruchart JC Davignon J Hermans MP , et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol 2014; 13: 26.

Rocha VZ Santos RD. Cholesterol and inflammation: the lesser the better in atherothrombosis. Eur J Prev Cardiol 2018; 25: 944–947.

Connolly SJ Eikelboom JW Bosch J , et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 205–218.

Tsimikas S Fazio S Ferdinand KC , et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018; 71: 177–192.

Fruchart JC Santos RD Aguilar-Salinas C , et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol 2019; 18: 71.

Robinson JG Williams KJ Gidding S , et al. Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein b lipoproteins earlier in life. J Am Heart Assoc 2018; 7: e009778.

Ference BA Bhatt DL Catapano AL , et al. Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA 2019; 322: 1381–1391.

Taylor F Huffman MD Macedo AF , et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816.

Ettehad D Emdin CA Kiran A , et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957–967.

Wang N Fulcher J Abeysuriya N , et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol 2020; 8: 36–49.

Cholesterol Treatment Trialists’ Collaborators, Mihaylova B Emberson J , et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581–590.

De Backer G. Epidemiology and prevention of cardiovascular disease: Quo vadis? Eur J Prev Cardiol 2017; 24: 768–772.

Kotseva KDBG De Bacquer D Ryden L , et al.; EUROASPIRE V Investigators. Primary prevention efforts are poorly developed in people at high cardiovascular risk. A report from the ESC-EORP EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol, Epub ahead of print 20 March 2020. DOI: 10.1177/2047487320908698.

Kalra R Parcha V Patel N , et al. Increased awareness, inadequate treatment, and poor control of cardiovascular risk factors in American young adults: 2005-2016. Eur J Prev Cardiol, Epub ahead of print 2 March 2020. DOI: 10.1177/2047487320905190.

Katz M Laurinavicius AG Franco FG , et al. Calculated and perceived cardiovascular risk in asymptomatic subjects submitted to a routine medical evaluation: the perception gap. Eur J Prev Cardiol 2015; 22: 1076–1082.

Lindahl B Norberg M Johansson H , et al. Health literacy is independently and inversely associated with carotid artery plaques and cardiovascular risk. Eur J Prev Cardiol 2020; 27: 209–215.

Alcala HE Albert SL Roby DH , et al. Access to care and cardiovascular disease prevention: a cross-sectional study in 2 Latino communities. Medicine (Baltimore) 2015; 94: e1441.